Navigation Links
S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
Date:12/1/2008

SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF).

The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients. The Phase 1 part of the study will assess the safety profile and evaluate the pharmacokinetic and pharmacodynamic activities of SB1518, and the Phase 2 component will assess the clinical benefits and continue to evaluate the safety profile of SB1518. The principal investigators are Dr. Andrew Roberts at the Royal Melbourne Hospital and Dr. John Seymour at the Peter MacCallum Cancer Centre.

"We are pleased with the advancement of our JAK2 inhibitor into a Phase 1/2 clinical trial in Australia as it exemplifies the expansion of our company's global development strategy," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "SB1518's strengths are in its exciting anti-proliferative and anti-tumor activity, as demonstrated by a range of in vitro and in vivo models, as well as its excellent tolerability. We believe this compound may eventually provide oncologists with a much needed and improved option to treat patients suffering from CIMF."

CIMF is a serious progressive and chronic condition whereby scar tissue develops in the bone marrow, resulting in a reduced ability to produce sufficient blood cells. Consequently, more blood cells are made in other organs, such as the liver and spleen which are not as efficient at blood cell production as the bone marrow. CIMF is characterized by an enlarged spleen and progressive anaemia. Current therapies for CIMF are mostly palliative in nature and survival rates can be short. While the actual cause of the disease is unknown, the JAK2 gene has been implicated i
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
2. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
5. Anpath Group, Inc. Advances Relationship With the Washington Metropolitan Area Transit Authority (Metro)
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
9. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
10. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
11. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... HILL, N.C. , June 18, 2013  Recent ... more difficult for Medical Education groups at large pharmaceutical ... on the safe and effective use of their new ... the pharma industry, it is crucial that these ... reaching healthcare professionals. To address the changes ...
(Date:6/18/2013)... , June 18, 2013  Women are frequently ... but unfortunately they often do not give the same ... have kept information from their doctor because they were ... according to a recent survey conducted by Allergan and ... dedicated to bringing education, funding and research to the ...
(Date:6/18/2013)... The board of directors of Eli Lilly ... a dividend for the third quarter of 2013 of ... The dividend is payable September 10, 2013 to ... August 15, 2013. Lilly, a leading innovation-driven ... by applying the latest research from its own worldwide ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 2New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 3New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 4New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 5New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 6New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 7New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 8New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 9
... RATE- MEDIAN SURVIVAL OF 10.5 MONTHS IN COMPLETE ... MEETINGSOUTH SAN FRANCISCO, Calif., March 3 Hana ... new positive preliminary efficacy results from a planned ... trial evaluating Marqibo(R) (vincristine sulfate liposomes injection) for ...
... Society of Gynecologic Oncologists (SGO) and the American College ... breast disease fellowship training program for gynecologic oncologists. ... program provides support for a gynecologic oncologist to complete ... of breast cancer and related disease. "As experts ...
Cached Medicine Technology:Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 2Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 3Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 4Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 5SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 2SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 3
(Date:6/19/2013)... June 19, 2013 Over the past ... Retailer industry has been growing at an annualized ... 2013. Many factors have supported the development of the ... retailed by drugstores; relatively higher drug prices in hospitals; ... government's support for the development of chain drug retailing ...
(Date:6/18/2013)... Chicago, IL (PRWEB) June 18, 2013 Exposed ... is helping thousands of acne suffers of all ages finally ... Unlike other acne treatment products, this new acne clearing system ... current acne, and prevent new acne from forming. ... , ExposedSkinCareReview.org believes these products are some of the most ...
(Date:6/18/2013)... Fla. (PRWEB) June 19, 2013 An ... When Linda Christina Beauregard was diagnosed with breast cancer, ... In her new book, “I Gave Myself Cancer, I ... Life” (published by Balboa Press), Beauregard explains how changing ... cancer. , "Sick people have been made to feel ...
(Date:6/18/2013)... Vienna, VA (PRWEB) June 18, 2013 As ... the increase in need for surgical equipment during childbirth comes ... the child from within the mother when she is unable ... difficult deliveries, they are associated with higher rates of complication ... addition to being harmful to the mother and child, forceps ...
(Date:6/18/2013)... Parker Waichman LLP , a ... victims injured by defective medical devices, reports that the ... bone graft products are now available. Published this week ... two studies serve up two key findings: There is ... and the traditional bone graft; and there is “substantial ...
Breaking Medicine News(10 mins):Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 2Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 3Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3
... , DUQUESNE, Pa., Sept. 22 Wherever you live, ... house. From pulling out blankets, replacing smoke detector batteries, varying the ... their home routines in the fall. , , ... , If you are one of the estimated 40-50 ...
... INDIANAPOLIS, Sept. 22 Eli Lilly and Company (NYSE: ... Lilly China, has been promoted to president, Lilly USA, LLC. Ricks ... Business Unit as part of a company reorganization announced Sept. 14. , ... to lead Lilly USA, which is considered Lilly,s largest established market. , ...
... SALEM, N.H., Sept. 22 ALPCO is pleased ... easy and accurate measurement of both active (7-36) GLP-1 ... , , GLP-1, an incretin hormone, has been a focus ... was approved by the FDA in 2006, and early clinical data demonstrates that ...
... Results from Australia,s largest study of young drivers have shown ... roads. According to researchers from The George Institute, young drivers ... in serious crashes than those in urban areas. ... today at the launch of the Young Driver Factbase ...
... HATBORO, Pa., Sept. 22 InfoLogix, Inc. (Nasdaq: ... for the healthcare and commercial industries, announced today that it ... a private, not-for-profit healthcare system serving the greater Philadelphia area, ... large-scale Electronic Medical Record (EMR) implementation. , , ...
... , , DURHAM, N.C., Sept. 22 ... chairman and CEO, Chris Stern, will present at an investor conferences in ... will be at the Zurich Airport Radisson Hotel and is scheduled for ... be open to interested investors. , , ...
Cached Medicine News:Health News:'Flip for Fall' Seasonal Household Tips Include Ten Million Reasons to Use Allergy-Protective Bedding 2Health News:'Flip for Fall' Seasonal Household Tips Include Ten Million Reasons to Use Allergy-Protective Bedding 3Health News:Lilly Announces New U.S. Affiliate Leader 2Health News:ALPCO Launches GLP-1 (Active 7-36) and (7-36 and 9-36) ELISA Kits 2Health News:Rural roads dangerous for young drivers 2Health News:InfoLogix Selected by Albert Einstein Healthcare Network for eLearning Modules to Support EMR Implementation 2Health News:InfoLogix Selected by Albert Einstein Healthcare Network for eLearning Modules to Support EMR Implementation 3
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
... PY series leads are implantable bipolar ... stimulation of either the atrium or ... screw can be extended or retracted ... lead tip contains an anti-chattering mechanism ...
Used with permanent pacing leads....
Medicine Products: